Physician profile
Prem C Chatpar
NPI 1093755050
$9,847.84
in general payments reported to CMS, 2019-2025
31 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,794 · 2020: $767 · 2021: $929 · 2022: $2,629 · 2023: $1,339 · 2024: $132 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.10 |
| Education | $170.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $2,749.41 | 2019 | |
| Abbvie INC. | $1,483.00 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $942.89 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Horizon Therapeutics Plc | $746.62 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $659.93 | 2020-2023 | Acthar |
| Janssen Biotech, INC. | $449.29 | 2019-2024 | Tremfya |
| Pfizer INC. | $428.90 | 2019-2023 | |
| Glaxosmithkline, LLC. | $351.31 | 2019-2023 | Benlysta |
| Lilly USA, LLC | $287.17 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $242.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.00 | 2020-2023 | Ofev |
| Novartis Pharmaceuticals Corporation | $211.51 | 2019-2023 | |
| Radius Health, INC. | $163.08 | 2020 | |
| Ucb, INC. | $133.40 | 2019-2023 | Cimzia |
| Fidia Pharma USA INC. | $106.93 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $64.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $58.39 | 2022 | |
| Medexus Pharma, INC. | $57.49 | 2019-2020 | |
| Depuy Synthes Sales INC. | $56.82 | 2021-2023 | Orthovisc |
| Hikma Pharmaceuticals USA | $45.94 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $45.70 | 2022 | |
| Bioventus LLC | $45.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.11 | 2020-2021 | |
| Genentech USA, INC. | $36.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.17 | 2021 | |
| Genzyme Corporation | $21.93 | 2023 | |
| Amarin Pharma, INC. | $16.50 | 2019 | |
| Lundbeck LLC | $16.02 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.14 | 2021 | |
| Aurinia Pharma U.S., INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Chatpar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.